Compare VLY & PTGX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | VLY | PTGX |
|---|---|---|
| Founded | 1927 | 2006 |
| Country | United States | United States |
| Employees | 3675 | N/A |
| Industry | Major Banks | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 7.6B | 6.4B |
| IPO Year | N/A | 2016 |
| Metric | VLY | PTGX |
|---|---|---|
| Price | $14.73 | $128.75 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 13 | 13 |
| Target Price | $14.65 | ★ $108.23 |
| AVG Volume (30 Days) | ★ 6.9M | 727.2K |
| Earning Date | 04-23-2026 | 05-07-2026 |
| Dividend Yield | ★ 3.31% | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | N/A | ★ 0.05 |
| Revenue | N/A | N/A |
| Revenue This Year | $23.58 | $874.25 |
| Revenue Next Year | $8.51 | N/A |
| P/E Ratio | ★ $13.14 | $2,632.40 |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $8.96 | $50.49 |
| 52 Week High | $14.94 | $131.87 |
| Indicator | VLY | PTGX |
|---|---|---|
| Relative Strength Index (RSI) | 61.76 | 74.08 |
| Support Level | $13.30 | $94.48 |
| Resistance Level | $14.83 | N/A |
| Average True Range (ATR) | 0.34 | 4.88 |
| MACD | 0.00 | 1.37 |
| Stochastic Oscillator | 82.28 | 86.62 |
Valley National Bancorp is a bank holding company that offers a full suite of national and regional banking solutions through various commercial, private banking, retail, insurance, and wealth management financial services products. It provides personalized service and customized solutions to assist its customers with their financial service needs. The group also offers niche financial services, including loan and deposit products for homeowners associations, cannabis-related business banking, and venture banking, which offers nationally. It manages its business operations under operating segments consisting of Consumer Banking; Commercial Banking; and Treasury and Corporate Other. The group generates the majority of its revenue from the Commercial Banking Segment.
Protagonist Therapeutics Inc is a biopharmaceutical company engaged in the discovery and development of peptide-based therapeutics using its proprietary technology platform. The company focuses on three therapeutic areas: inflammation and immunology, hematology, and metabolic diseases. Its pipeline includes clinical-stage and preclinical candidates such as rusfertide for polycythemia vera, icotrokinra for inflammatory diseases, and other programs targeting IL-17, obesity, and iron metabolism disorders, developed through internal research and strategic collaborations.